The companies aim to generate preclinical proof-of-concept data on SRB123 and quickly take it into clinical trials.

SunRock Biopharma has teamed up with China’s Escugen to co-develop SRB123, a first-in-class antibody-drug conjugate (ADC) targeting CCR9, an antigen which is tied to particularly hard-to-treat cancers ...

Sunrock Biopharma SL and Shanghai Escugen Biotechnology Co. Ltd. have joined forces in a strategic partnership to codevelop ...

SunRock Biopharma and Escugen have joined forces in a strategic partnership to co-develop SRB123, a First-in-Class ...